ABBV Add to watchlist $217.58 1.05 (-0.48%) Last updated: May 31, 2026 20:36
52-Week Range
$217.58
$181.73 $217.58 $244.81

Fundamentals Overview

AbbVie Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 106.1 P/B 14.04 P/S 6.12

Intrinsic value (DCF)

-35.1% downside vs price

Profitability

Net margin 5.8%

Risk (Beta)

0.31 — lower vol

Earnings & growth

EPS $2.05 Rev -9.7% Profit -61.5% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 59% confidence Risk: Lower Volatility — Beta 0.31. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: B-

Pressures (Sell):

DCF 35.1% downside vs price · Sentiment weakening (2 downgrades) · 3M vs S&P 500: -13.2%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$384.42B
P/E (TTM)
106.07
EPS (TTM)
$2.05
Dividend Yield
3.1%
52-Week Range
$181.73 - $244.81
Volume vs Avg
N/A
Beta
0.31

About

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCL...
Sector: Healthcare
Headquarters: US
Employees: 55,000
IPO Date: Jan 2013
Beta: 0.31 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B-. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 7, Hold: 1, Neutral: 5, Outperform: 4, Overweight: 12, Peer Perform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $141.28; current price is $217.58. That’s a -35.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 106.07
DCF value (model) $141.28 (-35.1% vs price)
PEG (TTM) N/A
P/B (TTM) 14.04
P/S (TTM) 6.12
P/FCF (TTM) 18.42
Liquidity & enterprise
Current Ratio (TTM) 0.8
Quick Ratio (TTM) 0.68
Cash Ratio (TTM) 0.22
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 5.79%
Gross margin (TTM) 70.68%
Operating margin (TTM) 27.6%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for ABBV.

Analyst Sentiment at a Glance

B- Sentiment Weakening
Buy 7Hold 1Neutral 5Outperform 4Overweight 12Peer Perform 1
1 upgrade, 2 downgrades
Price Target Consensus
Current $217.58
Median $260.00
Consensus $257.54
Low consensus $223.00
High consensus $298.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Evercore ISI Group maintain Outperform Outperform 2026-05-15
Piper Sandler maintain Overweight Overweight 2026-05-14
Evercore ISI Group maintain Outperform Outperform 2026-05-04
Guggenheim maintain Buy Buy 2026-05-01
Morgan Stanley maintain Overweight Overweight 2026-04-30
Canaccord Genuity maintain Buy Buy 2026-04-30
Cantor Fitzgerald maintain Overweight Overweight 2026-04-30
Piper Sandler maintain Overweight Overweight 2026-04-23
Guggenheim maintain Buy Buy 2026-04-10
Cantor Fitzgerald maintain Overweight Overweight 2026-04-08
Piper Sandler maintain Overweight Overweight 2026-02-18
Freedom Broker maintain Buy Buy 2026-02-17
Morgan Stanley maintain Overweight Overweight 2026-02-05
UBS maintain Neutral Neutral 2026-02-05
Evercore ISI Group maintain Outperform Outperform 2026-02-05
Citigroup maintain Neutral Neutral 2026-01-27
Wolfe Research downgrade Outperform Peer Perform 2026-01-08
Morgan Stanley maintain Overweight Overweight 2025-12-12
HSBC upgrade Hold Buy 2025-12-10
Freedom Broker maintain Buy Buy 2025-11-12
UBS maintain Neutral Neutral 2025-11-07
Piper Sandler maintain Overweight Overweight 2025-11-05
Citigroup maintain Neutral Neutral 2025-11-03
JP Morgan maintain Overweight Overweight 2025-11-03
Guggenheim maintain Buy Buy 2025-10-20
Raymond James maintain Outperform Outperform 2025-10-17
Piper Sandler maintain Overweight Overweight 2025-10-10
Cantor Fitzgerald maintain Overweight Overweight 2025-10-09
B of A Securities maintain Neutral Neutral 2025-10-03
HSBC downgrade Buy Hold 2025-10-01